Treatment of invasive fungal infections in intensive care units with micafungin: The MYRIADE study

Autor:	Bertrand Gachot, Jean-François Timsit, Noel Milpied, Guy Leverger
Rok vydání:	2020
Předmět:	Adult Male 0301 basic medicine medicine.medical_specialty Antifungal Agents Adolescent Treatment duration 030106 microbiology Dermatology Young Adult 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Intensive care Internal medicine Humans Medicine Candidiasis Invasive Prospective Studies Aged Aged 80 and over business.industry Micafungin General Medicine Middle Aged Clinical Practice Intensive Care Units Treatment Outcome Infectious Diseases Tolerability Current practice Population study Female Observational study France business Invasive Fungal Infections medicine.drug
Zdroj:	Mycoses. 63:443-451
ISSN:	1439-0507 0933-7407
Popis:	Invasive fungal infections (IFIs) contribute significantly to nosocomial illness in intensive care units (ICUs). Current practice guidelines recommend echinocandins, such as micafungin, for the treatment of invasive candidiasis. However, limited information on their use in real-world practice is available.To describe the conditions of the use of micafungin in daily clinical practice and to evaluate its effectiveness and tolerability under real-world conditions.This observational, prospective, multicentre study was performed in 34 ICUs in France. The study population consisted of 275 patients ≥16 years old who received treatment with micafungin during the inclusion period. Dose and duration of treatment were at the discretion of the physician.Proven invasive candidiasis was documented before treatment in 106 patients (38.6%); 263 patients (95.6%) received the recommended dose (100 mg/day); 78 patients (28.8%) were treated for the recommended duration. A successful outcome was observed for 217 patients (79.2%). This proportion was significantly higher (83.3%; P .0001) in patients treated for ≥14 days. Three patients discontinued treatment due to an adverse event considered related to micafungin. No clear impact of micafungin on hepatic function was observed.Micafungin was effective in75% of patients treated for IFIs in ICUs in France; outcomes may be improved with closer adherence to the recommended treatment duration.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8fe5c4e286b1a24095bd7ab5d465349 https://doi.org/10.1111/myc.13060 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.